Quarterly ResultMay 5, 2026, 05:07 PM
Viemed Q1 Revenue +28% to $75.4M; Raises 2026 Revenue Guidance
AI Summary
Viemed Healthcare, Inc. announced strong financial results for the first quarter of 2026, with net revenues increasing 28% year-over-year to $75.4 million. The company reported net income of $2.6 million and a 12% increase in Adjusted EBITDA to $14.3 million, despite a non-recurring gain in the prior year. Operational growth was driven by a 57% rise in PAP therapy patients and a 47% increase in sleep resupply patients. Viemed also updated its full-year 2026 guidance, narrowing and raising its net revenue outlook and reaffirming Adjusted EBITDA.
Key Highlights
- Net revenues increased 28% to $75.4 million for Q1 2026.
- Net income attributable to Viemed was $2.6 million, or $0.06 per diluted share.
- Adjusted EBITDA grew 12% to $14.3 million.
- PAP therapy patient count increased 57% to 35,938 as of March 31, 2026.
- Sleep resupply patient count increased 47% to 33,661 as of March 31, 2026.
- Repurchased 150,000 common shares for $1.4 million at $9.29 per share.
- Full-year 2026 net revenue guidance raised to $312 million to $320 million.
- Full-year 2026 Adjusted EBITDA guidance reaffirmed at $65 million to $69 million.